Next Article in Journal
Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
Next Article in Special Issue
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Previous Article in Journal
Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse
Previous Article in Special Issue
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma

Epigenetics and Colorectal Cancer Pathogenesis

Department of Biochemistry and Molecular Biology, Medical College of Georgia, and Cancer Center, Georgia Regents University, Augusta, GA 30912, USA
Author to whom correspondence should be addressed.
Cancers 2013, 5(2), 676-713;
Received: 21 March 2013 / Revised: 22 May 2013 / Accepted: 24 May 2013 / Published: 5 June 2013
(This article belongs to the Special Issue Cancer Epigenetics)
Colorectal cancer (CRC) develops through a multistage process that results from the progressive accumulation of genetic mutations, and frequently as a result of mutations in the Wnt signaling pathway. However, it has become evident over the past two decades that epigenetic alterations of the chromatin, particularly the chromatin components in the promoter regions of tumor suppressors and oncogenes, play key roles in CRC pathogenesis. Epigenetic regulation is organized at multiple levels, involving primarily DNA methylation and selective histone modifications in cancer cells. Assessment of the CRC epigenome has revealed that virtually all CRCs have aberrantly methylated genes and that the average CRC methylome has thousands of abnormally methylated genes. Although relatively less is known about the patterns of specific histone modifications in CRC, selective histone modifications and resultant chromatin conformation have been shown to act, in concert with DNA methylation, to regulate gene expression to mediate CRC pathogenesis. Moreover, it is now clear that not only DNA methylation but also histone modifications are reversible processes. The increased understanding of epigenetic regulation of gene expression in the context of CRC pathogenesis has led to development of epigenetic biomarkers for CRC diagnosis and epigenetic drugs for CRC therapy. View Full-Text
Keywords: colorectal cancer; DNMT; HDAC; HMTase; epigenetic therapy colorectal cancer; DNMT; HDAC; HMTase; epigenetic therapy
Show Figures

Figure 1

MDPI and ACS Style

Bardhan, K.; Liu, K. Epigenetics and Colorectal Cancer Pathogenesis. Cancers 2013, 5, 676-713.

AMA Style

Bardhan K, Liu K. Epigenetics and Colorectal Cancer Pathogenesis. Cancers. 2013; 5(2):676-713.

Chicago/Turabian Style

Bardhan, Kankana, and Kebin Liu. 2013. "Epigenetics and Colorectal Cancer Pathogenesis" Cancers 5, no. 2: 676-713.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop